Medicines informal market in Congo, Burundi and Angola: Counterfeit and sub-standard antimalarials

Malaria Journal

Volumn 6, Issue , 2007, Pages

  Gaudiano, Maria Cristina ^a   Di Maggio, Anna ^a   Cocchieri, Emilia ^a   Antoniella, Eleonora ^a   Bertocchi, Paola ^a   Alimonti, Stefano ^a   Valvo, Luisa ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; EXCIPIENT; ILLICIT DRUG; MEFLOQUINE; PYRIMETHAMINE; QUININE; SULFADOXINE;

ANGOLA; ARTICLE; BIOEQUIVALENCE; BURUNDI; CONGO; DRUG BIOAVAILABILITY; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG PACKAGING; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; LIQUID CHROMATOGRAPHY; QUALITY CONTROL; VALIDATION STUDY;

ANGOLA; ANTIMALARIALS; BURUNDI; CHROMATOGRAPHY; CONGO; DRUG LABELING; DRUG PACKAGING; HUMANS; QUALITY CONTROL; SOLUBILITY; TABLETS;

EID: 33847610276     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-6-22     Document Type: Article

References (29)

1. Effective medicines regulation: ensuring safety, efficacy and quality. World Health Organization, Geneva: World Health Organization, WHO/EDM/2003.2 1999
2. Specifications for prepackaging antimalarial medicines. World Health Organization, Geneva: World Health Organization, WHO/HTM/MAL/2005.1100 1999
3. Stability of drugs in tropics. A study in Sudan. IO Abu Reid SA El-Samani Al Hag Omer NY Khalil KM Mahgoub G Everitt K Grundstrom B Lindgren NE Stjernstrom, Int Pharm J 1990 4 6 10
4. In vitro evaluation of the quality of essential drugs on the Tanzanian market. PG Risha D Shewiyo A Msami G Masuki G Vergote C Vervaet JP Remon, Trop Med Int Health 2002 7 701 707 10.1046/j.1365-3156.2002.00937.x 12167097
5. Counterfeits kill. International Council of Nurses, Geneva: International Council of Nurses 2005
6. Counterfeit drugs: implications for health. M Ten Ham, Adverse Drug React Toxicol Rev 1992 11 59 65 1606284
7. Substandard and counterfeit medicines. World Health Organization, Geneva: World Health Organization, Fact Sheet no. 275 2003
8. Counterfeit Drugs. Guidelines for the development of measures to combat counterfeit drugs. World Health Organization, World Health Organization, WHO/EDM/QSM/99.1 1999
9. Counterfeit drugs. World Health Organization, Bull World Health Organ 1993 71 464 466 8324864
10. Counterfeit and sub-standard drugs in Myanmar and Vietnam. E Wondemagegnehu, Geneva: World Health Organization, WHO/EDM/QSM/99.3 1999
11. Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania. YA Abdi G Rimoy O Ericsson C Alm AY Massele, Lancet 1995 346 1161 10.1016/S0140-6736(95)91834-5 7475622
12. Assessment of the incidence of substandard drugs in developing countries. O Shakoor RB Taylor RH Behrens, Trop Med Int Health 1997 2 839 845 10.1046/j.1365-3156.1997.d01-403.x 9315042
13. Fake antimalaria drugs in Cambogia. J Rogendaal, Lancet 2001 357 890 10.1016/S0140-6736(05)71830-4
14. Fake artesunate in southeast Asia. P Newton S Proux M Green F Smithuis J Rozendaal S Prakongpan K Chotivanich M Mayxay S Looareesuwan J Farrar F Nosten NJ White, Lancet 2001 357 1948 1950 10.1016/S0140-6736(00)05085-6 11425421
15. Sao Paulo Epidemic of counterfeit drugs causes concern in Brazil. C Csillag, Lancet 1998 352 553 10.1016/S0140-6736(05)79267-9 9716071
16. China cracks down on counterfeit medicines. R Tomlinson, BMJ 1999 318 624 10066194
17. Substandard tuberculosis drugs on the global market and their simple detection. KF Laserson AS Kenyon TA Kenyon T Layloff NJ Binkin, Int J Tuberc Lung Dis 2001 5 7 448 454 11336276
18. Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region. I Petralanda, Lancet 1995 345 1433 10.1016/S0140-6736(95) 92620-8 7677844
19. Drug quality, a contributor to drug resistance? RB Taylor O Shakoor RH Behrens, Lancet 1995 346 122 10.1016/S0140-6736(95)92145-1 7603195
20. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. AM Dondorp PN Newton M Mayxay W Van Damme FM Smithuis S Yeung A Petit AJ Lynam A Johnson TT Hien R McGready JJ Farrar S Looareesuwan NPJ Day MD Green NJ White, Trop Med Int Health 2004 9 1241 1246 10.1111/j.1365-3156.2004. 01342.x 15598255
21. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. LK Basco, Am J Trop Med Hyg 2004 70 245 250 15031511
22. Note for guidance on the investigation of bioavailability and bioequivalence. European Medicines Agency, Quality Working Party Guidelines London: European Medicines Agency, CPMP/EWP/QWP/1401/98 2001
23. Development and validation of a reversed-phase LC method for analysing potentially counterfeit antimalarial medicines. MC Gaudiano E Antoniella P Bertocchi L Valvo, J Pharm Biomed Anal 2006 42 132 135 10.1016/j.jpba.2006.01. 059 16517111
24. USP 29. NF 24. The official compendia of standards. Rockville: United States Pharmacopeial Convention, Inc 2006
25. Uniformity of mass of single dose preparations. European Directorate for the Quality of Medicines, European Pharmacopoeia Strasbourg: EDQM 5 2006
26. Disintegration of tablets and capsules. European Directorate for the Quality of Medicines, European Pharmacopoeia Strasbourg: EDQM 5 2006
27. European Directorate for the Quality of Medicines, European Pharmacopoeia Strasbourg: EDQM 5 2006
28. British Pharmacopoeia London: British Pharmacopoeia Commission 2004
29. World Health Organization, International Pharmacopoeia Geneva: World Health Organization Third 2003